Valuation: DexCom, Inc.

Market Cap 31.5B 28.32B 26.43B 23.95B 44.97B 2,998B 45.25B 317B 124B 1,556B 118B 116B 5,004B P/E 2026 *
33.5x
P/E 2027 * 28.3x
Enterprise Value 30.74B 27.64B 25.79B 23.37B 43.88B 2,925B 44.16B 310B 121B 1,518B 115B 113B 4,883B EV / Sales 2026 *
5.88x
EV / Sales 2027 * 5.25x
Free-Float
91.27%
Yield 2026 *
-
Yield 2027 * -
1 week-0.93%
Current month-3.24%
1 month-1.38%
3 months+12.73%
6 months+32.72%
Current year+25.84%
1 week 83.02
Extreme 83.02
86.32
1 month 82.92
Extreme 82.92
90.36
3 years 54.12
Extreme 54.12
141.7
5 years 18.1
Extreme 18.096875
164.61
10 years 10.66
Extreme 10.655
164.61
Manager TitleAgeSince
Chief Executive Officer 47 2025-12-31
Director of Finance/CFO 46 2021-03-18
Chief Tech/Sci/R&D Officer - 2024-04-30
Director TitleAgeSince
Chairman 68 2018-07-29
Director/Board Member 67 2009-11-19
Director/Board Member 47 2025-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-1.83%+2.04%+26.18%+9.56% 31.5B
+0.35%+4.29%-22.74%+13.32% 178B
+1.31%+10.20%-2.39%+30.95% 121B
-0.33%+2.26%-23.89%+9.21% 108B
+0.37%+3.95%-44.99%-10.25% 75.7B
+1.84%+5.96%+5.74%+77.89% 64.15B
-1.75%-0.28%+16.15%+64.07% 53.49B
+0.81%+4.85%+0.28%-26.98% 51.45B
+1.67%+4.41%-16.94%+24.13% 41.68B
-1.87%-0.98%+26.07%+9.56% 31.5B
Average +0.47%+3.49%-3.65%+20.14% 80.52B
Weighted average by Cap. +0.74%+4.21%-10.76%+19.79%

Financials

2026 *2027 *
Net sales 5.23B 4.7B 4.39B 3.98B 7.47B 498B 7.51B 52.66B 20.56B 258B 19.63B 19.21B 831B 5.79B 5.21B 4.86B 4.41B 8.27B 551B 8.32B 58.33B 22.78B 286B 21.75B 21.28B 920B
Net income 973M 875M 816M 740M 1.39B 92.6B 1.4B 9.8B 3.83B 48.06B 3.65B 3.57B 155B 1.15B 1.03B 961M 871M 1.64B 109B 1.65B 11.54B 4.5B 56.59B 4.3B 4.21B 182B
Net Debt -761M -684M -639M -579M -1.09B -72.43B -1.09B -7.66B -2.99B -37.59B -2.86B -2.8B -121B -1.06B -954M -891M -807M -1.52B -101B -1.52B -10.69B -4.17B -52.43B -3.99B -3.9B -169B
Projected Income Statement - Annual - DexCom, Inc.
Logo DexCom, Inc.
DexCom, Inc. specializes in the design, manufacture and marketing of continuous glucose monitoring (CGM) systems for people with diabetes and healthcare providers. The company provides an implantable device for continuous measurement of blood glucose levels and an external transmitter to which the sensor transmits glucose levels at specified intervals. The United States accounts for 71.5% of net sales.
Employees
-
Date Price Change
26-10-14 US$83.52 -1.83%
26-10-13 US$85.08 -0.99%
26-10-12 US$85.93 +2.20%
26-10-09 US$84.08 -0.42%
26-10-08 US$84.44 +0.16%
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - DexCom, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
83.47USD
Average target price
96.46USD
Spread / Average Target
+15.56%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - DexCom, Inc.